Savara Inc. $SVRA Shares Sold by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. trimmed its position in Savara Inc. (NASDAQ:SVRA) by 14.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,862,301 shares of the company’s stock after selling 1,600,000 shares during the period. Savara comprises about 1.6% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 18th largest holding. Frazier Life Sciences Management L.P. owned approximately 4.85% of Savara worth $59,470,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Prudential Financial Inc. acquired a new stake in Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets boosted its holdings in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP acquired a new stake in Savara in the 2nd quarter worth about $33,000. Russell Investments Group Ltd. boosted its holdings in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in Savara in the 3rd quarter worth about $44,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Stock Down 0.2%

Savara stock opened at $5.26 on Friday. Savara Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $7.01. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The firm has a 50 day moving average price of $5.29 and a 200 day moving average price of $5.60. The company has a market capitalization of $1.08 billion, a PE ratio of -9.39 and a beta of 0.26.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Research analysts expect that Savara Inc. will post -0.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Oppenheimer started coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. William Blair set a $10.00 target price on shares of Savara in a research note on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Savara in a research note on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.